MSCL Stock Overview
A biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Satellos Bioscience Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.53 |
| 52 Week High | CA$0.80 |
| 52 Week Low | CA$0.29 |
| Beta | 1.17 |
| 11 Month Change | 3.92% |
| 3 Month Change | -5.36% |
| 1 Year Change | 6.00% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -70.39% |
Recent News & Updates
Shareholder Returns
| MSCL | CA Biotechs | CA Market | |
|---|---|---|---|
| 7D | 0% | -1.3% | 0.7% |
| 1Y | 6.0% | -44.0% | 8.3% |
Return vs Industry: MSCL exceeded the Canadian Biotechs industry which returned -41.1% over the past year.
Return vs Market: MSCL underperformed the Canadian Market which returned 8.4% over the past year.
Price Volatility
| MSCL volatility | |
|---|---|
| MSCL Average Weekly Movement | 9.8% |
| Biotechs Industry Average Movement | 12.3% |
| Market Average Movement | 8.2% |
| 10% most volatile stocks in CA Market | 16.8% |
| 10% least volatile stocks in CA Market | 3.0% |
Stable Share Price: MSCL has not had significant price volatility in the past 3 months.
Volatility Over Time: MSCL's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | n/a | Frank Gleeson | satellos.com |
Satellos Bioscience Inc., a biotechnology company, develops regenerative therapeutics to treat degenerative muscle diseases primarily in Canada and Australia. The company uses its proprietary platform MyoReGenX, an automated microscopy system which recapitulates the muscle stem cell environment ex-vivo. Its lead program focuses on the discovery and development of a small molecule drug for the treatment of Duchenne.
Satellos Bioscience Inc. Fundamentals Summary
| MSCL fundamental statistics | |
|---|---|
| Market cap | CA$58.65m |
| Earnings (TTM) | -CA$21.13m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.8x
P/E RatioIs MSCL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MSCL income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$13.82m |
| Gross Profit | -CA$13.82m |
| Other Expenses | CA$7.31m |
| Earnings | -CA$21.13m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.19 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MSCL perform over the long term?
See historical performance and comparison